Free Trial

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$3.54 -0.23 (-6.10%)
As of 07/7/2025 04:00 PM Eastern

DSGN vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYRE

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Design Therapeutics vs. Its Competitors

Design Therapeutics (NASDAQ:DSGN) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Design Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.

Design Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 12.99%. Oculis has a consensus target price of $35.33, suggesting a potential upside of 88.55%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oculis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Oculis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Design TherapeuticsN/AN/A-$49.59M-$0.99-3.58
OculisN/AN/A-$97.43M-$2.64-7.10

In the previous week, Oculis had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 1 mentions for Oculis and 0 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.00 equaled Oculis'average media sentiment score.

Company Overall Sentiment
Design Therapeutics Neutral
Oculis Neutral

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 31.2% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Design Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Design Therapeutics' return on equity of -22.85% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Design TherapeuticsN/A -22.85% -22.02%
Oculis -13,788.70%-92.95%-70.03%

Summary

Design Therapeutics beats Oculis on 9 of the 13 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$214.02M$2.91B$5.51B$9.02B
Dividend YieldN/A2.44%5.24%4.05%
P/E Ratio-3.5820.4427.2120.09
Price / SalesN/A190.28370.4792.99
Price / CashN/A41.7026.2128.59
Price / Book0.837.397.945.55
Net Income-$49.59M-$55.04M$3.17B$248.49M
7 Day Performance0.57%2.51%1.79%4.87%
1 Month Performance-11.72%-0.21%1.27%6.63%
1 Year Performance1.14%3.41%33.56%20.38%

Design Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
0.8243 of 5 stars
$3.54
-6.1%
$4.00
+13.0%
+3.5%$214.02MN/A-3.5840
OCS
Oculis
1.7349 of 5 stars
$18.74
-1.4%
$35.33
+88.5%
+60.7%$829.58MN/A-7.102
CMRX
Chimerix
0.627 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6877 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
QURE
uniQure
2.1019 of 5 stars
$14.31
-0.8%
$37.82
+164.3%
+272.7%$789.86M$27.12M-3.26500
CRMD
CorMedix
2.7461 of 5 stars
$11.42
-1.7%
$17.14
+50.1%
+177.2%$788.13M$82.55M51.9130
CRON
Cronos Group
2.0063 of 5 stars
$2.04
flat
N/A-8.5%$786.79M$117.61M15.69450
GHRS
GH Research
1.5777 of 5 stars
$15.01
+0.7%
$32.00
+113.2%
+27.7%$776MN/A-19.0010Analyst Upgrade
SNDX
Syndax Pharmaceuticals
3.1324 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-58.3%$774.43M$23.68M-2.26110
IMNM
Immunome
2.4292 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-27.8%$769.19M$9.04M-2.7340
GYRE
Gyre Therapeutics
0.0862 of 5 stars
$7.62
-6.3%
N/A-38.7%$762.25M$105.76M381.1940

Related Companies and Tools


This page (NASDAQ:DSGN) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners